PhenomeX Merger Solicitation Lacks Key Financial Data, Suit Says

PhenomeX Inc., a cell biology research company, and its directors allegedly misled investors in documents related to a proposed merger with Bruker Corp, a shareholder suit filed Friday says.

The companies agreed last month that Bruker would acquire PhenomeX for $1.00 per share of common stock, but filed a solicitation for shareholders to approve the transaction that left out key financial information, the suit filed in US District Court for the District of Delaware says.

Bruker’s tender offer is set to expire on Sept. 28, but shareholders can’t make an informed decision whether to tender their shares until ...